Discover
Inside 340B Report
Inside 340B Report
Author: 340B Report
Subscribed: 3Played: 84Subscribe
Share
© 2025
Description
Inside 340B Report is your exclusive, behind-the-scenes window into the latest news and developments in the 340B drug pricing program, straight from the journalists at 340B Report. Each episode, published twice a month, brings listeners inside 340B Report's newsroom for a candid, insider's perspective on the evolving drug pricing policy landscape from the journalists who cover it daily.
52 Episodes
Reverse
In this episode, 340B Report Publisher and CEO Ted Slafsky joins Editor-in-Chief Will Newton, Managing Editor Shannon Young and National Correspondent Luke Zarzecki in breaking down the latest 340B news, including a high-stakes Maine federal court hearing on the Health Resources and Services Administration's (HRSA) revamped 340B rebate pilot, efforts in Congress to block the rebate pilot before the end of the year and the result of a hospital lawsuit challenging Eli Lilly's 340B data requirements. Key Topics Covered: Maine Fed. Court Hearing Rematch on Rebates Shannon, Will and Ted discuss the recent oral arguments before a Maine federal district court judge in an American Hospital Association-led lawsuit that aims to temporarily halt the Trump administration's new 340B rebate model pilot from taking effect on Jan. 1, 2027. Shannon notes how the Nov. 18 oral arguments compared to those in a similar 2025 lawsuit that went before the same federal judge. Will and Ted share their observations from the hearing and the three discuss what the judge's questions and comments to attorneys during the hearing could signal for hospitals' efforts to once again block HRSA's rebate pilot. Congressional Efforts to Halt 340B Rebates Luke breaks down a newly unveiled must-pass U.S. Senate spending bill and its accompanying explanatory statement that raises concerns over the 340B rebate model and drugmaker 340B contract pharmacy restrictions. He also details 340B provider groups' requests for a key bipartisan Senate group to include language in any year-end package that either delays or ends the 340B rebate model. Shannon discusses the potential implications of passing a continuing resolution versus a larger appropriations package, as well as how the Democrats' majority in the next Congress could affect future legislation come January. 340B Data Lawsuit Dismissed: Will breaks down a Florida federal judge's recent ruling to dismiss a hospital lawsuit challenging Eli Lilly's in-house pharmacy 340B claims data requirements. He explains that the judge ruled that covered entities cannot use state law to enforce the 340B statute, citing a U.S. Supreme Court decision. Will also notes that two other hospitals have ongoing lawsuits against Lilly, and that multiple state attorneys general are pursuing enforcement actions against the Indiana-based drugmaker, as well. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This episode is brought to you by one of our great Ultra Diamond sponsors, VytlOne. As the only independent provider of integrated pharmacy solutions, VytlOne leads the way in partnering with hospitals, health systems and health centers to unlock pharmacy revenue, strengthen local care and reinvest in communities. We are very grateful to VytlOne for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.
In this episode, 340B Report Publisher and CEO Ted Slafsky joins Editor-in-Chief Will Newton, Managing Editor Shannon Young and National Correspondent Luke Zarzecki in breaking down the latest 340B news, including two new Centers for Medicare and Medicaid Services (CMS) final rules with major 340B implications; what the 2026 congressional midterm elections could mean for the future of 340B policy; and CVS Health's surprise move to split off its businesses into two companies. Ted also reflects on Inside 340B Report's 50th episode milestone and thanks the behind-the-scenes team that makes sure listeners can benefit from this show. Key Topics Covered: CMS Releases Final Rules Affecting 340B Will breaks down the new CMS rule to slash Medicare Part B reimbursement to certain types of 340B hospitals by around 32% starting next year. Ted looks back at the previous efforts to block the first Trump administration's Part B cuts and predicts there will be similar legal and legislative efforts this time as well. Will also explains CMS' other new rule creating a mandatory 340B data repository for Part D claims, including how it differs from other reporting requirements. Congressional Bills and Midterm Outcomes Shannon, Luke and Ted discuss the outcomes of the historic midterm elections and what they could mean for 340B policy on Capitol Hill in 2027. Shannon highlights key races in the U.S. House, while Luke breaks down the results from the U.S. Senate. Ted offers insights into what 340B observers could expect to see happen on the policy front in the 120th Congress. The three also discuss two recently introduced federal bills that would halt the Trump administration's 340B rebate model pilot from taking effect as planned on Jan. 1, 2027. CVS Breaks Up Will details CVS Health's recently announced move to split into two separate companies in 2028, and what that could mean for 340B stakeholders. He also notes that CVS' 340B practices have faced increasing scrutiny, including from a series of health system lawsuits alleging the company conspired to lower 340B contract pharmacy reimbursement owed to those hospitals. Will notes that CVS has denied those claims. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This episode is brought to you by one of our great Ultra Diamond sponsors, Pillr Health. Pillr is a leading provider of innovative solutions designed to optimize and streamline pharmacy operations with a focus on enhancing efficiency, reducing costs and improving patient outcomes, particularly within the 340B program. We are very grateful to Pillr Health for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.
In this episode, 340B Report Publisher and CEO Ted Slafsky joins Editor-in-Chief Will Newton, Managing Editor Shannon Young and National Correspondent Luke Zarzecki in breaking down the latest 340B news, including legal challenges and legislation that aim to stop the Trump administration's 340B rebate model pilot from taking effect in January. They also discuss the upcoming midterm elections, and what they could mean for 340B policy; a U.S. House Democrat priorities memo that includes 340B-related actions; and the controversy surrounding Amgen's new healthcare encounter and services claims data requirements. Key Topics Covered: Actions to Halt the 340B Rebate Model Pilot Will breaks down the American Hospital Association (AHA)-led lawsuit seeking to block the Health Resources and Services Administration's (HRSA) 340B rebate pilot from taking effect on Jan. 1. He also discusses a federal judge's recent order allowing drug manufacturers to join the case as intervenors to defend the pilot. Meanwhile, Luke details the newly unveiled 340B Rebate Model Delay Act, a U.S. House bill which would delay the Trump administration's 340B rebate model pilot, or "any substantially similar" rebate program until Dec. 31, 2028. Midterm Elections Shannon and Ted preview how the Nov. 3 midterm elections could affect 340B policy. Shannon notes the lawmakers up for reelection who serve on the U.S. House and Senate committees overseeing 340B—and who could be tapped to lead those panels depending on the election outcomes. Ted breaks down how election analysts expect the midterms to go for each party and how a close U.S. Senate race in Kansas could affect 340B policy on Capitol Hill in the next Congress. Shannon also discusses U.S. House Democrats' top healthcare priorities for the 120th Congress, including a September letter lawmakers sent to House Minority Leader Hakeem Jeffries (D-N.Y.) that called for immediate actions to bolster the 340B program and halt the Trump administration's 340B rebate model pilot. Amgen's New Requirements Will details Amgen's new healthcare visit and service claims data requirements set to take effect in mid-November and explains why those requirements are more expansive than other drugmaker policies. Additionally, Luke discusses the National Association of Community Health Centers' letter asking HRSA to review the policy and direct Amgen to halt the requirements before they take effect next month. 340B Report's Midterm Webinar Ted previews 340B Report's Nov. 10 subscriber-only webinar, which will dive into the midterm election results and what they mean for state and federal 340B policy in 2027 and beyond. He notes that the editorial team will also break down the major 340B changes on the horizon, including the latest news on the 340B rebate model and its legal challenges. Subscribers can learn more and register for the webinar by logging into 340B Report. Prospective subscribers can learn more about this exciting event by visiting 340B Report and taking advantage of a 25% discount on subscriptions. They can then benefit from all our must-watch webinars and other valuable services available only to subscribers. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This episode is brought to you by one of our great Ultra Diamond sponsors, Verity Solutions. Verity Solutions' innovative, award-winning 340B program management solutions are designed to optimize 340B pharmacy spend and maximize pharmacy supply chain savings. We are very grateful to Verity Solutions for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.
In this episode, 340B Report Publisher and CEO Ted Slafsky joins Editor-in-Chief Will Newton and National Correspondent Luke Zarzecki in breaking down the latest 340B news, including the newly-approved manufacturer 340B rebate pilot plans. They also discuss a new multi-organization community health center letter to Congressional leadership shared exclusively with 340B Report; the Pharmaceutical Research and Manufacturers of America's (PhRMA) new CEO; a 340B child site litigation update; and two 340B developments in the states. Key Topics Covered: HRSA's Rebate Pilot Plans Will breaks down the Health Resources and Services Administration's (HRSA) recently approved manufacturer 340B rebate pilot plans. He also explains why two drugmakers may have chosen not to include their eligible drugs in the pilot. Meanwhile, Luke details a new letter from more than 50 community health center associations representing over 1,500 health centers asking certain U.S. House leaders to hold a hearing on the "impending implementation" of the 340B rebate model pilot. PhRMA's New Leader Luke discusses PhRMA's new President and CEO Eric Cantor, who formerly served in Congress as the House Majority Leader for Republicans from 2011 to 2014. Cantor was not active in 340B policy during his time on the Hill, but usually backed the drug industry in other policy areas. Ted provides his take on PhRMA's choice during the current political environment. 340B Child Site Ruling Appeal Will explains the latest in HRSA's appeal of a Washington, D.C., federal court ruling that struck down the agency's 340B hospital offsite clinic registration policy. He breaks down why the ruling was a victory for hospitals, as well as why both HRSA and PhRMA are arguing the ruling should be overturned. Will also discusses an amicus brief from four manufacturers taking a different approach. State 340B Updates Luke breaks down two new similar bills introduced in each chamber of the Pennsylvania legislature. Both bills would prohibit manufacturers from restricting delivery of 340B drugs to covered entities or their contract pharmacies and ban 340B claims data requirements not required under federal law, among other changes. Will then breaks down an Arkansas' federal judge's ruling in favor of that state's 340B contract pharmacy access law, and the history of that state's litigation. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This episode is brought to you by one of our great Ultra Diamond sponsors, RxParadigm. RxParadigm's mission is to cultivate innovative approaches and technologies that promote transparency and authenticity, leading to enhanced outcomes, reduced overall healthcare costs and effective 340B program administration. We are very grateful to RxParadigm for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.
In this episode, 340B Report Publisher and CEO Ted Slafsky joins Editor-in-Chief Will Newton, Managing Editor Shannon Young and National Correspondent Luke Zarzecki in breaking down the latest 340B news, including: 340B Report's scoop that the Trump administration is reportedly planning to shift 340B oversight to the U.S. Centers for Medicare and Medicaid Services (CMS); reactions to a proposal to slash Medicare Part B reimbursement for 340B hospitals; two major 340B legal developments; and a recap of 340B Report's latest webinar. Key Topics Covered: Shifting 340B Oversight? Will details 340B Report's recent news alert reporting that the Trump administration plans to shift 340B oversight from its longtime home at the Health Resources and Services Administration (HRSA) to CMS this month. HRSA and CMS have not confirmed the report, which was based on a conversation with a source familiar with the plans. Will also explains why many 340B providers are concerned with the potential shift. Competing Takes on 340B Hospital Cuts Shannon discusses concerns 340B hospitals and New York congressional Republicans raised in public comments on CMS' proposed 2027 Hospital Outpatient Prospective Payment System rule, which would cut Medicare Part B reimbursement for 340B-acquired outpatient drugs. Meanwhile, Luke and Ted note that other stakeholders—including a private oncology practice group and a trade association of for-profit hospitals—have supported the move. 340B in the Courts Will breaks down two recent federal district court rulings dismissing manufacturer challenges to Colorado's 340B access law. He also shares an update on Sanofi's ongoing lawsuit against HRSA seeking providers' pharmacy services agreements. Will notes that HRSA has recently contacted multiple providers about these contracts, which Sanofi argues could reveal that covered entities transfer the title of 340B drugs to contract pharmacies in violation of the 340B statute. 340B Report's New Explainer Luke gives kudos to the editorial team on their recent webinar covering the 340B program's history and major tension points for both subscribers and nonsubscribers. He also discusses 340B Report's new explainer, which breaks down 340B program history, operations, oversight, key tension points and other important details. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This episode is brought to you by one of our great Ultra Diamond sponsors, PharmaForce. PharmaForce is the only third-party administrator composed entirely of experienced 340B professionals developing uniquely flexible technology solutions for covered entities and pharmacies of every size. We are very grateful to PharmaForce for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.



